Etanercept
| EAS | Nº pacientes | Respuesta terapéutica n (%) |
Efectos adversos n (%) |
Mortalidad |
|---|---|---|---|---|
Still adulto |
35 |
57,14% |
22,85% |
0 |
Wegener |
89 |
69,66% |
23,59% |
2 |
Sjögren |
29 |
31,03% |
10.34% |
0 |
Sarcoidosis |
30 |
26,66% |
16,66% |
0 |
Behçet |
26 |
96,15% |
3,84% |
0 |
Esclerorsis sistémica |
18 |
83,33% |
11,11% |
0 |
Dermatomiositis |
14 |
21,42% |
14,28 |
0 |
IBM |
9 |
0% |
0% |
0 |
Crioglobulinemia |
6 |
100% |
0% |
0 |
LES |
3 |
100% |
0% |
0 |
| PAN | 1 |
100% |
100% |
0 |
| Policondritis | 1 |
100% |
100% |
0 |
| Polimialgia reumática | 6 |
83,33% |
50% |
0 |
Churg-Strauss |
1 |
100% |
0% |
0 |
Horton |
9 |
55,55% |
88,88% |
0 |
Polimiositis |
8 |
87,5% |
37,5% |
0 |
TOTAL |
285 |
60% |
20% |
2 (0,7%) |